TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05667701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soy isoflavone
Description: Soy isoflavone supplement (Novasoy) that contains isoflavones (genistein, daidzein, glycetein) given at a dose of genistein aglycone equivalents to provide the genistein dosing of 22.6 mg/day for children aged 2-10 months, and 30.3 mg/day children aged 10-24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: A matching placebo also administered twice daily.
Study: NCT00673751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-2
Description: 450 nmol subcutaneous
Study: NCT05904171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tangotherapy
Description: Learning and practicing a series of moves - both individual and with a partner - taken from Argentine Tango, according to the Riabilitango (R) approach. The training is aimed at improving both physical (e.g., balance, change of direction, coordination, endurance) and cognitive (i.e., learning, divided attention, inhibition, planning) domains, in a pleasant, enjoyable, and inclusive environment.~This group-based training will take place twice a week (1h each session), for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Walking and stretching in group twice a week (1h each session), for 6 weeks.
Study: NCT00673751

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05498103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methazolamide 25 MG
Description: 25 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methazolamide 50 MG
Description: 50 mg tablets
Study: NCT06247007

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: LI-4, LI-11, GV-14, GV-20 acupuncture points were needled bilaterally.
Study: NCT04739293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON123300
Description: ON 123300 hard gelatin capsules
Study: NCT05019196

Intervention type: DEVICE
Intervention: GE 3.0T MRI
Description: using GE 3.0T MRI to obtain anatomical and functional MR images and DTI images
Study: NCT05314842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: dressing agents in pulpotomized primary molas using formocresol in cariously exposed vital primary molars

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premixed bioceramic MTA
Description: dressing agents in pulpotomized primary molas using premixed bioceramic MTA in cariously exposed vital primary molars
Study: NCT04999358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protein education
Description: The protein education session is pre-recorded and will describe in lay terms: the health issues associated with low protein intake, the amount of protein to eat in a day, and provide useful information to increase protein intake. This information will focus on the quality and amount of protein eaten, primarily using a whole-food approach. For example, the education sessions will give ideas for everyday foods that can be added to regular meals, favouring plant proteins, fish, lean meat, poultry, low fat dairy and eggs. The education session has been provided in conjunction with an NHS dietitian.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard education
Description: Dietary advice provided as part of standard cardiac rehabilitation will be pre-recorded and provided to the control group. This education session will be in addition to usual care.
Study: NCT04758767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CID-103
Description: anti-CD38 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CID-103
Description: anti-CD38 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CID-103
Description: anti-CD38 antibody
Study: NCT04699357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: different concentrations (0.01%/0.04%/0.1%) of atropine were administered to high myopic children
Study: NCT05516017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Electrical Stimulator and Pinhole Glasses
Description: It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.~The pinhole glasses are made of 2 pieces of opaque black plastic material with a total of 113 holes on each side. The opaque black plastic is 1.7 mm thick, 4.5 cm wide, and 5.5 cm long.~The holes in the opaque black material are arranged horizontally in 11 rows from top to bottom. The diameter of each hole is 1.1 mm, the horizontal distance of the holes from each other is 4.5 mm, and the vertical distance is 3.5 mm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Electrical Stimulator
Description: It is applied with a vestibular electrical stimulation device for 20 msec with 2 Hz, 1-4 mA, 1 mA increments. Very high frequencies can cause auditory perceptions such as 0.5 - 20 kHz, should be avoided.
Study: NCT06624943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biosimilar insulin glargine
Description: Once daily injection of biosimilar insulin glargine via reusable pen
Study: NCT05694897

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae block using bupivacaine 0.25% and magnesium sulfate
Description: After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus 3.75 ml NS and 125 mg MgSO4 (1.25ml).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae block using bupivacaine and dememdetomidine
Description: After induction of general anesthesia the patients will be flipped to the prone position and ESP block was performed using, a high frequency linear ultrasound probe placed longitudinally 2 to 3 cm lateral to the 10th thoracic vertebrae, and the trapezius and erector Spinae muscles identified.~An 18-G Tuohy needle passed along the plane of the transducer until its tip hit the transverse process of T10; the needle was then withdrawn slightly.~Total volume of 25 ml was injected including 20 mL 0.25% bupivacaine plus dexmedetomidine 1ug/kg.
Study: NCT06160622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leritrelvir
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leritrelvir
Description: Oral
Study: NCT05872529

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education which consists processed EEG monitoring and SBI approach
Study: NCT04683809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Patients will attend rehabilitation sessions through online programmes for rehabilitation
Study: NCT06459830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mime Therapy with Neural Mobilization
Description: Experimental group will receive mime therapy and neural mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Facial Neural Mobilization:~Facial mobilization technique will apply when the patient in supine position with head on the table in neural rotation.~The circular movement and horizontal traction will be applied 25 times in three sets with a 5-second rest period in between a single manipulation and a 30- second rest period in between the sets.~All the participates in the experimental group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mime Therapy with Placebo Mobilization
Description: Control group will receive mime therapy and placebo nerve mobilization session with small resting intervals.~Self- facial massages for 10 minutes. Breathing and relaxation exercises for 5 mins. Exercises to enhance coordination between both sides of the face and to reduce synkinesis.~Exercises to assist with eye and lip closure for 5 mins. Articulation Exercises for 5 mins. Facial expression exercises for 10 mins.~Placebo Nerve Mobilization Technique:~The placebo nerve mobilization followed all the procedures of real nerve mobilization without applying horizontal and circular auricular traction. The purpose of this placebo nerve mobilization is not to deprived the control group from therapy and equalize the time duration of treatment protocol.~All the participates in the control group will receive 15 treatment sessions. Each session will held for 60 minutes per day, 5 days per week, for total duration of 3 weeks.
Study: NCT05486442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT for weight-related experiential avoidance
Description: Participants in the experimental group received weight concern-related ACT training in a group setting. Each session focused on different dimensions of ACT and included relevant exercises and homeworks. Dimensions studied included creative hopelessness, control strategies, mindfulness exercises, values and barries to values and commitment to action.
Study: NCT06459895

Intervention type: DIAGNOSTIC_TEST
Intervention: Long non-coding MALAT1 gene expression assay:
Description: RNA extraction (isolation from whole blood) II-Synthesis of CDNA from RNA by reverse transcription III-Gene expression assay by RT-PCR reaction

Intervention type: DIAGNOSTIC_TEST
Intervention: Long non-coding MALAT1 gene expression assay:
Description: RNA extraction (isolation from whole blood) II-Synthesis of CDNA from RNA by reverse transcription III-Gene expression assay by RT-PCR reaction
Study: NCT06416813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GDMT+DCB
Description: Preventive Intervention on Eligible Vulnerable Plaques Using DCB
Study: NCT04787471

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 30 minute photoactivation of riboflavin 0.1%
Description: Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 10 minute photoactivation of riboflavin 0.1%
Description: Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
Study: NCT05829980

Intervention type: PROCEDURE
Intervention: Laser assisted in-situ keratomileusis
Description: Laser-Assisted In Situ Keratomileusis is a procedure that permanently changes the shape of the cornea using an excimer laser and the mechanical microkeratome (a blade device) used to cut a flap in the cornea.

Intervention type: PROCEDURE
Intervention: Laser assisted in-situ keratomileusis
Description: Laser-Assisted In Situ Keratomileusis is a procedure that permanently changes the shape of the cornea using an excimer laser and the mechanical microkeratome (a blade device) used to cut a flap in the cornea.
Study: NCT05110846

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05829980

Intervention type: PROCEDURE
Intervention: Photorefractive keratectomy
Description: Photorefractive keratectomy is a laser refractive procedure used to ablate the corneal stroma to correct refractive errors without cutting flap

Intervention type: PROCEDURE
Intervention: Photorefractive keratectomy
Description: Photorefractive keratectomy is a laser refractive procedure used to ablate the corneal stroma to correct refractive errors without cutting flap
Study: NCT05885919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Dexborneol Concentrated Solution for injection
Description: Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Edaravone Dexborneol placebo
Description: Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
Study: NCT04238299

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiparametric renal MRI
Description: Localiser scans; Kidney volume; Longitudinal (T1) relaxation time mapping; Diffusion weighted imaging (DWI); Phase Contrast MRI; Arterial spin labelling (ASL); Blood Oxygen Level Dependent (BOLD) mapping
Study: NCT05422742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP + MM
Description: Subjects will be randomized into either SRP only or SRP +MM. Periodontal therapy will consist of one visit full-month SRP alone or in-combination with MM placed at all sites regardless of probing pocket depth. Each site will recieve 1mg of MM for a total of 6mg of MM per tooth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Description: Procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation.
Study: NCT04919044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery Training
Description: The number of imagined contractions were 34 trials, each trial was 10 seconds with 5seconds rest between each trial and 2 minutes' rest was given after first 17 trials.
Study: NCT04130958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)
Description: iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)
Description: iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
Study: NCT05110846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-868
Description: CT-868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-868
Description: CT-868
Study: NCT04130958

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)
Description: The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)
Description: The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
Study: NCT05674578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Assigned a patient navigator and receive coaching
Study: NCT05852028

Intervention type: DRUG
Intervention: Selinexor
Description: this is a real-world. Patients who use selinexor-based regimens in lymphoma will be followed up without interfering with the choice of treatment options for patients
Study: NCT04488003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Oral, 600 mg, twice daily, for 28-days in each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Oral, 600 mg, twice daily, for 28-days in each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician's Choice
Description: Physician's choice will be restricted to two approved (not off-label) treatments for each tumor histology (agents targeting BRAF or MEK kinases and experimental agents are not permitted as physician choice)).
Study: NCT05069025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.

Intervention type: OTHER
Group type: OTHER
Intervention: no-music
Description: Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
Study: NCT05674578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05872867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WM-A1-3389
Description: Anti-IGSF1 (Immunoglobulin superfamily member 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WM-A1-3389
Description: Anti-IGSF1 (Immunoglobulin superfamily member 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-1(Programmed cell death protein 1)
Study: NCT05599087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular system
Description: Regenerative Endodontic Procedure Tissue engineering procedure
Study: NCT04713592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study: NCT04960553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exufiber® and Mepilex® Border Flex
Description: Post Market Clinical Follow-up Investigation applying Exufiber® and Mepilex® Border Flex to 102 subjects who meet the study criteria for up to 12 weeks
Study: NCT06035003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Mindfulness Intervention for Emotional Distress (iMIED)
Description: Internet-based Mindfulness Intervention for Emotional Distress (iMIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
Study: NCT04359030

Intervention type: DIAGNOSTIC_TEST
Intervention: Multislice CT scanning for aortic wall calcification
Description: Multislice CT scanning for aortic wall calcification
Study: NCT06396923

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wingate test
Description: Wingate Anaerobic Power Test is based on maximal pedaling on a bicycle ergometer against a predetermined constant load to provide the highest mechanical power for 30 seconds. During the test, measurements are made automatically at intervals of five seconds and six equal intervals. As a result of these measurements, some data are obtained that allow us to obtain information about anaerobic performance.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Wingate test
Description: Wingate Anaerobic Power Test is based on maximal pedaling on a bicycle ergometer against a predetermined constant load to provide the highest mechanical power for 30 seconds. During the test, measurements are made automatically at intervals of five seconds and six equal intervals. As a result of these measurements, some data are obtained that allow us to obtain information about anaerobic performance.
Study: NCT04359030

Intervention type: DIAGNOSTIC_TEST
Intervention: Multislice CT scanning for aortic wall calcification
Description: Multislice CT scanning for aortic wall calcification

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic stress echocardiography
Description: Transthoracic stress echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic stress echocardiography
Description: Transthoracic stress echocardiography
Study: NCT05975437

Intervention type: OTHER
Intervention: personalized surveillance plans (PSP) and personalized aftercare plans (PAP)
Description: The PSP contains decisions on the surveillance trajectory based on individual risks and needs, assessed with the 'Breast Cancer Surveillance Decision Aid' including the INFLUENCE prediction tool. The PAP contains decisions on the aftercare trajectory based on individual needs and preferences and available care resources, which decision-making is supported by a patient decision aid.
Study: NCT06315803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time 3D Xplane ultrasound
Description: After the puncture needle is in the skin, the longitudinal section of the Xplane mode can be adjusted to keep the needle in the proposed plane.
Study: NCT05863286

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botulinum toxin is produced by the gram-positive, anaerobic, spore-forming bacterium Clostridium botulinum, and is one of the most lethal biological toxins known to man.~Botulinum toxin has seven antigenically different serotypes and exerts a paralytic action by rapidly and strongly binding to presynaptic cholinergic nerve terminals. It is then internalized and ultimately inhibits the exocytosis of acetylcholine by decreasing the frequency of acetylcholine release. Without its nerve supply, the muscle fiber will deteriorate; however, the muscle will regain its strength as the nerves regenerate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin is produced by the gram-positive, anaerobic, spore-forming bacterium Clostridium botulinum, and is one of the most lethal biological toxins known to man.~Botulinum toxin has seven antigenically different serotypes and exerts a paralytic action by rapidly and strongly binding to presynaptic cholinergic nerve terminals. It is then internalized and ultimately inhibits the exocytosis of acetylcholine by decreasing the frequency of acetylcholine release. Without its nerve supply, the muscle fiber will deteriorate; however, the muscle will regain its strength as the nerves regenerate.